X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Inhibitor Therapeutics licenses U.S Patent for New Angiogenesis Inhibitors from JHU, for use of SUBA-Cap (itraconazole) in Prostate Cancer, Basal Cell Carcinoma including Basal Cell Carcinoma Nevus Syndrome (an orphan oncology disease), and Lung Cancer.
Lead Product(s): Itraconazole
Therapeutic Area: Oncology Product Name: SUBA-Cap
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Johns Hopkins University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 13, 2023
Details:
Phase 2b clinical trial will evaluate the efficacy and safety of SUBA-Itraconazole capsules dosed in combination with docetaxel and prednisone in patients with metastatic castrate resistant prostate cancer.
Lead Product(s): Itraconazole,Docetaxel,Prednisone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
